Viridian Details Phase 3 Program for Thyroid Eye Disease

 

• On track to initiate two phase 3 clinical trials of VRDN-003 in August 2024
• REVEAL-1 and REVEAL-2, will evaluate two active dosing regimens of subcutaneously (SC) administered VRDN-003 in active and chronic thyroid eye disease (TED), with topline readout anticipated in the first half of 2026 for both trials
• VRDN-003 Biologics License Application (BLA) submission anticipated by year-end 2026
• VRDN-003 is the only half-life extended anti-IGF-1R antibody in clinical development with the potential for convenient SC dosing as infrequently as every 8 weeks, for a total of 3 administrations

https://www.biospace.com/article/releases/viridian-therapeutics-announces-details-of-subcutaneous-vrdn-003-phase-3-clinical-program-for-patients-with-active-and-chronic-moderate-to-severe-thyroid-eye-disease/